Dick Pluim

The Effect of Low pH on Breast Cancer Resistance Protein (ABCG2)-Mediated Transport of Methotrexate, 7-Hydroxymethotrexate, Methotrexate Diglutamate, Folic Acid, Mitoxantrone, Topotecan, and Resveratrol in In Vitro Drug Transport Models

Jos H. Beijnen, Piet Borst, Gerrit Jansen, 2007, Molecular Pharmacology.

In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2

Jos H. Beijnen, Alfred H. Schinkel, J. Schellens, 2007, Molecular Cancer Therapeutics.

New insights into the pharmacology and cytotoxicity of gemcitabine and 2′,2′-difluorodeoxyuridine

Jos H. Beijnen, Jashvant D. Unadkat, J. Schellens, 2008, Molecular Cancer Therapeutics.

A phase 0 clinical trial of novel candidate extended-release formulations of capecitabine

Jos H. Beijnen, J. Schellens, H. Rosing, 2016, Cancer Chemotherapy and Pharmacology.

Improved pharmacodynamic (PD) assessment of low dose PARP inhibitor PD activity for radiotherapy and chemotherapy combination trials.

Conchita Vens, Heike Peulen, J. Schellens, 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.